Paulo César Cesar Giraldo

Prof. Dr. Paulo César Cesar Giraldo


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
MBMarcela Bardin
Marcela Bardin
PGPaulo César Cesar Giraldo
Paulo César Cesar Giraldo
LBLuiz Gustavo Oliveira Brito
Luiz Gustavo Oliveira Brito
ECEtienne Santos Cordeiro
Etienne Santos Cordeiro
RARose Amaral
Rose Amaral
MMMélanie Morin
Mélanie Morin

19 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JJJOSE Eleutério Junior
JOSE Eleutério Junior
PGPaulo César Cesar Giraldo
Paulo César Cesar Giraldo
RERenata Mírian Nunes Eleutério
Renata Mírian Nunes Eleutério
CTCristiana Rodrigues Teófilo
Cristiana Rodrigues Teófilo
Important gaps remain in our understanding of the composition of the vaginal virome, its interactions with the bacterial microbiome and the host immune system, and its implications for vaginal homeostasis, human papillomavirus (HPV) persistence, and obstetric outcomes. The vaginal virome is a dynamic component of the female genital ecosystem, comprising eukaryotic viruses, bacteriophages, and endogenous viral elements. Recent evidence suggests that alterations in viral composition and diversity may influence the stability of the vaginal microbiome and mucosal immune responses, thereby increasing susceptibility to clinically relevant disorders. Increased viral diversity has been associated with vaginal dysbiosis, persistent HPV infection, and adverse pregnancy outcomes, including preterm birth. In parallel, bacteriophage-based therapies and recombinant endolysins have shown promise for the selective treatment of bacterial biofilms associated with bacterial vaginosis. The vaginal virome is an integral component of the microbial ecology of the female genital tract. A better understanding of its interactions with the bacterial microbiome and the host immune system may facilitate the development of diagnostic biomarkers and innovative therapeutic strategies for precision medicine in women's health.

15 September 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
JJJOSE Eleutério Junior
JOSE Eleutério Junior
PGPaulo César Cesar Giraldo
Paulo César Cesar Giraldo
RERenata Mírian Nunes Eleutério
Renata Mírian Nunes Eleutério
CTCristiana Rodrigues Teófilo
Cristiana Rodrigues Teófilo
Important gaps remain in our understanding of the vaginal virome. Its composition, interactions with the bacterial microbiome and host immune system, and implications for vaginal homeostasis, human papillomavirus (HPV) persistence, and obstetric outcomes remain incompletely defined. The vaginal virome is a dynamic component of the female genital ecosystem. It includes viruses that infect human cells, bacteriophages, and endogenous viral elements. Observational studies have associated altered viral composition or diversity with vaginal dysbiosis, persistent HPV detection, and adverse pregnancy outcomes, including preterm birth. These relationships remain correlative, and causality has not been established. Bacteriophage-based therapies and recombinant endolysins may selectively target bacterial biofilms associated with bacterial vaginosis. However, most applications remain preclinical or in early clinical development. Better characterization of the interactions among viruses, bacteria, epithelial cells, and mucosal immunity may support future diagnostic biomarkers and precision therapeutic strategies in women’s health.